TY  - GEN
AU  - Hamid,Omid
AU  - Robert,Caroline
AU  - Daud,Adil
AU  - Hodi,F Stephen
AU  - Hwu,Wen-Jen
AU  - Kefford,Richard
AU  - Wolchok,Jedd D
AU  - Hersey,Peter
AU  - Joseph,Richard W
AU  - Weber,Jeffrey S
AU  - Dronca,Roxana
AU  - Gangadhar,Tara C
AU  - Patnaik,Amita
AU  - Zarour,Hassane
AU  - Joshua,Anthony M
AU  - Gergich,Kevin
AU  - Elassaiss-Schaap,Jeroen
AU  - Algazi,Alain
AU  - Mateus,Christine
AU  - Boasberg,Peter
AU  - Tumeh,Paul C
AU  - Chmielowski,Bartosz
AU  - Ebbinghaus,Scot W
AU  - Li,Xiaoyun Nicole
AU  - Kang,S Peter
AU  - Ribas,Antoni
TI  - Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
SN  - 1533-4406
PY  - 2013///0725
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Agents
KW  - Brain Neoplasms
KW  - secondary
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Male
KW  - Melanoma
KW  - drug therapy
KW  - Middle Aged
KW  - Programmed Cell Death 1 Receptor
KW  - antagonists & inhibitors
KW  - Skin Neoplasms
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1056/NEJMoa1305133
ER  -